ArticlePharmaceutical research2009
Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule.
Article in Pharmaceutical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Targeted gene delivery systems for T-cell engineering.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- A biomaterial platform for T cell-specific gene delivery.Acta biomaterialia · 2024Article
- Bioinspired engineering of fusogen and targeting moiety equipped nanovesicles.Nature communications · 2023Article
- Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering.Journal for immunotherapy of cancer · 2023Article
- Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Antigen identification and high-throughput interaction mapping by reprogramming viral entry.Nature methods · 2022Article
- V-CARMA: A tool for the detection and modification of antigen-specific T cells.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells.Journal for immunotherapy of cancer · 2021Article
- Genetic in vivo engineering of human T lymphocytes in mouse models.Nature protocols · 2021Article
- Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors.Blood advances · 2020Article
- Role of circular RNAs in brain development and CNS diseases.Progress in neurobiology · 2020Review
- Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes.Molecular therapy. Methods & clinical development · 2019Review
- Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors.Acta naturae · 2013Article
- Pseudotyping lentiviral vectors with aura virus envelope glycoproteins for DC-SIGN-mediated transduction of dendritic cells.Human gene therapy · 2011Article
- Immunization delivered by lentiviral vectors for cancer and infectious diseases.Immunological reviews · 2011Review
- Lentiviral vectors for immune cells targeting.Immunopharmacology and immunotoxicology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe purpose of this study was to investigate the potential of a T-cell-related targeting method using a lentiviral vector-based gene delivery system. MATERIALS AND
methodsA lentiviral vector system was constructed by co-incorporating an anti-CD3 antibody (OKT3) and a fusogen into individual viral particles. The incorporation of OKT3 and fusogen was analyzed using confocal microscopy and the in vitro transduction efficiency was evaluated using flow cytometry. Blocking reagents (ammonium chloride (NH(4)Cl) and soluble OKT3 antibody) were added into vector supernatants during transduction to study the mechanism of this two-molecule targeting strategy. To demonstrate the ability of targeted transduction in vivo, Jurkat.CD3 cells were xenografted subcutaneously into the right flank of each mouse and the lentiviral vector was injected subcutaneously on both sides of each mouse 8 h post-injection. Subsequently, the reporter gene (firefly luciferase) expression was monitored using a noninvasive bioluminescence imaging system.
resultsBy co-displaying OKT3 and fusogen on the single lentiviral surface, we could achieve targeted delivery of genes to CD3-positive T-cells both in vitro and in vivo.
conclusionsThese results suggest the potential utility of this engineered lentiviral system as a new tool for cell type-directed gene delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.